-
Discontinuation of First-Line MS Treatments: A Change in Patient Care Paradigm
24 Apr 2024 13:57 GMT
… identify why patients stopped injectable MS treatments and how this impacted their …
-
These Analysts Revise Their Forecasts On Biogen After Q1 Results
25 Apr 2024 13:11 GMT
… (down 4% on constant currency). Multiple sclerosis drug Tysabri sales were down to $431 …
-
Ancient DNA Decoded: Tracing Neurodegenerative Diseases to Prehistoric Herders
25 Apr 2024 12:07 GMT
… it has many applications beyond MS research.”
The team now plans to …
-
PET Scans Reveal ‘smoldering’ Inflammation in patients with Multiple sclerosis
25 Apr 2024 10:25 GMT
… treated with the most effective MS treatments available were experiencing worsening symptoms …
-
Sanofi profit slips on generic competition and currency effects
25 Apr 2024 08:29 GMT
… and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of …
-
Future Parents More Likely to Get RSV Vaccine When Pregnant if Aware That RSV Can Be a Serious Illness in Infants
25 Apr 2024 09:07 GMT
… author Jennifer Kusma Saper, MD, MS, researcher at Mary Ann & J …
-
Sanofi Q1 profit slips on generic competition, forex effects
25 Apr 2024 06:03 GMT
… effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of …
-
Roche's Vabysmo shows no sign of slowdown after Regeneron and Bayer's launch of Eylea HD
24 Apr 2024 23:25 GMT
… Wednesday.
Roche’s top product, multiple sclerosis treatment Ocreuvus, rang up sales of …
-
Roche cuts drug pipeline in effort to revitalise business
24 Apr 2024 22:06 GMT
… of estimates. Sales of its multiple sclerosis treatment Ocrevus increased by 8 per …
-
Biogen: Don’t expect any big acquisitions this year
24 Apr 2024 21:51 GMT
… Spinraza and a slate of multiple sclerosis drugs gives it “legitimacy in being …